The early start of hemoperfusion decreases the mortality rate among severe COVID-19 patients: A preliminary study.
Hemodial Int
; 26(2): 176-182, 2022 04.
Article
in English
| MEDLINE | ID: covidwho-1570641
ABSTRACT
BACKGROUND:
Coronavirus disease-2019 (COVID-19)-related organ failure is partly related to a sepsis-like syndrome and extreme pro-inflammatory cytokine release, named cytokine storm. Therapeutic strategies that prevent the production of or remove the pro-inflammatory cytokines could potentially be an effective therapy in critically afflicted COVID-19 patients.METHODS:
In this clinical trial study, from April until June 2020, 68 COVID-19 patients (35 vs. 33 controls) with severe critical symptoms, and PaO2 /FiO2 (P/F) ratio less than 200 mmHg either received a single standard therapy or a combination of standard treatment for COVID-19 combined with hemoperfusion (hemofilter, HA330 D Javfron) for 4 h, in 3 consecutive days. The length of hospital stay and mechanical ventilation, the resolution of radiologic abnormalities, and the mortality rate were defined as the primary outcomes.RESULTS:
Demographic characteristics, the acute physiology, and chronic health evaluation score of both groups were similar (p > 0.05). Importantly, we noticed a significant mortality rate reduction in the perfused group compared with controls (37.1% vs. 63.6%, p = 0.02), this positive effect was stronger among those with a P/F ratio higher than 75 (mortality rate of 84.7% for P/F ratio < 75 vs. 15.4% for P/F ratio ≥ 75, p = 0.02).CONCLUSIONS:
The results imply that early start of hemoperfusion could be more effective and significantly reduce the mortality rate among COVID-19 patients with critical diseases.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Hemoperfusion
/
COVID-19
Type of study:
Experimental Studies
/
Prognostic study
/
Randomized controlled trials
Limits:
Humans
Language:
English
Journal:
Hemodial Int
Journal subject:
Nephrology
/
Therapeutics
Year:
2022
Document Type:
Article
Affiliation country:
Hdi.12982
Similar
MEDLINE
...
LILACS
LIS